Letaplimab represents a significant step in the battle against C3-mediated illnesses. This novel monoclonal antibody targets the alternative pathway, a critical component of the biological pathway, offering a https://tayacwfj806042.blog5.net/92076344/letaplimab-a-exciting-new-approach